Literature DB >> 10340391

PTEN/MMAC1 mutations in hepatocellular carcinomas.

Y J Yao1, X L Ping, H Zhang, F F Chen, P K Lee, H Ahsan, C J Chen, P H Lee, M Peacocke, R M Santella, H C Tsou.   

Abstract

Mutations in the PTEN/MMAC1 gene have been identified in several types of human cancers and cancer cell lines, including brain, endometrial, prostate, breast, thyroid, and melanoma. In this study, we screened a total of 96 hepatocellular carcinoma (HCC) samples from Taiwan, where HCC is the leading cancer in males and third leading cancer in females, for mutations in the PTEN/MMAC1 gene. Complete sequence analysis of these samples demonstrated a missense mutation in exon 5 (K144I) and exon 7 (V255A) from HCC samples B6-21 and B6-2, respectively. A putative splice site mutation was also detected in intron 3 from sample B6-2. Both B6-21 and B6-2 were previously shown to contain missense mutations in the coding sequences of the p53 gene. Functional studies with the two missense mutations demonstrated that while mutation V255A in exon 7 resulted in a loss of phosphatase activity, mutation K144I in exon 5 retained its phosphatase activity. Additionally, we identified a silent mutation (P96P) in exon 5 of the PTEN/MMAC1 gene from HCC sample B6-22. These data provide the first evidence that the PTEN/MMAC1 gene is mutated in a subset of HCC samples.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10340391     DOI: 10.1038/sj.onc.1202659

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  31 in total

1.  The phosphoinositide 3-kinase regulatory subunit p85alpha can exert tumor suppressor properties through negative regulation of growth factor signaling.

Authors:  Cullen M Taniguchi; Jonathon Winnay; Tatsuya Kondo; Roderick T Bronson; Alexander R Guimaraes; José O Alemán; Ji Luo; Gregory Stephanopoulos; Ralph Weissleder; Lewis C Cantley; C Ronald Kahn
Journal:  Cancer Res       Date:  2010-06-08       Impact factor: 12.701

2.  A PTEN inhibitor displays preclinical activity against hepatocarcinoma cells.

Authors:  Giuseppa Augello; Roberto Puleio; Maria Rita Emma; Antonella Cusimano; Guido R Loria; James A McCubrey; Giuseppe Montalto; Melchiorre Cervello
Journal:  Cell Cycle       Date:  2016       Impact factor: 4.534

Review 3.  Beta-catenin signaling, liver regeneration and hepatocellular cancer: sorting the good from the bad.

Authors:  Kari Nichole Nejak-Bowen; Satdarshan P S Monga
Journal:  Semin Cancer Biol       Date:  2010-12-21       Impact factor: 15.707

4.  PTEN in liver diseases and cancer.

Authors:  Marion Peyrou; Lucie Bourgoin; Michelangelo Foti
Journal:  World J Gastroenterol       Date:  2010-10-07       Impact factor: 5.742

Review 5.  Tumor suppressor and hepatocellular carcinoma.

Authors:  Juliette Martin; Jean-Francois Dufour
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

6.  Transcriptional repression by RB-E2F and regulation of anchorage-independent survival.

Authors:  J T Yu; R G Foster; D C Dean
Journal:  Mol Cell Biol       Date:  2001-05       Impact factor: 4.272

7.  Correlation between loss of PTEN expression and PKB/AKT phosphorylation in hepatocellular carcinoma.

Authors:  Zhifang Yang; Jilin Yi; Xingrui Li; Wei Long
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2005

Review 8.  Molecular signalling in hepatocellular carcinoma: Role of and crosstalk among WNT/ß-catenin, Sonic Hedgehog, Notch and Dickkopf-1.

Authors:  Alex Giakoustidis; Dimitrios Giakoustidis; Satvinder Mudan; Argyrios Sklavos; Roger Williams
Journal:  Can J Gastroenterol Hepatol       Date:  2015-05

9.  Identification of PTEN mutations in metastatic melanoma specimens.

Authors:  J T Celebi; I Shendrik; D N Silvers; M Peacocke
Journal:  J Med Genet       Date:  2000-09       Impact factor: 6.318

10.  Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas.

Authors:  Yasuo Horie; Akira Suzuki; Ei Kataoka; Takehiko Sasaki; Koichi Hamada; Junko Sasaki; Katsunori Mizuno; Go Hasegawa; Hiroyuki Kishimoto; Masahiro Iizuka; Makoto Naito; Katsuhiko Enomoto; Sumio Watanabe; Tak Wah Mak; Toru Nakano
Journal:  J Clin Invest       Date:  2004-06       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.